Given the pivotal role of STAT3 in multiple myeloma initiation and progression, the aim of our study was to investigate whether GAC 17:1 can exert its anti-tumor activity through the attenuation of the STAT3 signaling pathway in multiple myeloma cells. Here, STAT3 is linked to plasma cell myeloma.